|
Press Releases |
|
 |
|
Wednesday, April 9, 2025 |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
中國抗體製藥有限公司SM17治療特應性皮炎1b期概念驗證臨床試驗取得突破性結果 |
中國抗體製藥有限公司(「中國抗體」或「本公司」;股份代號:3681)宣佈,其SM17針對中重度特應性皮炎(AD)的創新療法已完成1b期臨床研究,並獲得突破性頂線數據結果。 more info >> |
|
中国抗体制药有限公司SM17治疗特应性皮炎1b期概念验证临床试验取得突破性结果 |
中国抗体制药有限公司(“中国抗体”或“本公司”;股份代号:3681)宣布,其SM17针对中重度特应性皮炎(AD)的创新疗法已完成1b期临床研究,并获得突破性顶线数据结果。 more info >> |
|
Tuesday, April 16, 2024 |
|
中国抗体SM17治疗特应性皮炎(AD)之临床前结果刊登于国际科学期刊《Allergy》 |
more info >> |
|
中國抗體SM17治療特應性皮炎(AD)之臨床前結果刊登於國際科學期刊《Allergy》 |
more info >> |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
中国抗体SM17新药研究申请再获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗特应性皮炎(“AD”)的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”) more info >> |
|
中國抗體SM17新藥研究申請再獲國家藥監局批准 |
專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司—中國抗體製藥有限公司(上市編號:3681.HK,下稱「中國抗體」或「本公司」)欣然宣佈,本公司所提交之治療特應性皮炎(「AD」)的同類首創(First-in-Class)治療產品SM17的新藥研究申請(「新藥研究申請」) more info >> |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
中国抗体SM17针对治疗哮喘疾病的新药研究申请获国家药监局批准 |
专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司—中国抗体制药有限公司(上市编号:3681.HK,下称“中国抗体”或“本公司”)欣然宣布,本公司所提交之治疗哮喘的同类首创(First-in-Class)治疗产品SM17的新药研究申请(“新药研究申请”)于2023年8月11日获中国国家药品监督管理局(“国家药监局”)批准。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
AI產業延續高景氣 明略科技講出企業級「DeepSeek+Manus」好故事
Apr 24, 2025 10:50 HKT/SGT
|
|
|
AI产业延续高景气 明略科技讲出企业级「DeepSeek+Manus」好故事
Apr 24, 2025 10:44 HKT/SGT
|
|
|
NEC invests in U.S.-based "Geodesic Alliance Fund" aiming to strengthen economic security business
Apr 24, 2025 10:23 JST
|
|
|
MHI Thermal Systems Wins German Red Dot Design Award 2025
Apr 24, 2025 10:11 JST
|
|
|
Waterloo Startup Axibo AI Secures $12M to Pioneer 'Made in Canada' Humanoids
Apr 24, 2025 09:10 HKT/SGT
|
|
|
ULVAC Develops Dilution Refrigerator for Quantum Computers
Apr 24, 2025 9:30 JST
|
|
|
EdgePoint Towers advances renewable energy integration in telecommunications with first solar hybrid deployment
Apr 24, 2025 07:46 HKT/SGT
|
|
|
Batch Bicycles and Hyatt Place Zhuhai jointly organized An Exhalating Cycling Event in Macau
Apr 24, 2025 07:33 HKT/SGT
|
|
|
百琦自行車與珠海橫琴凱悅酒店聯合舉辦騎行澳門活動
Apr 23, 2025 18:32 HKT/SGT
|
|
|
百琦自行车与珠海横琴凯悦酒店联合举办骑行澳门活动
Apr 23, 2025 18:23 HKT/SGT
|
|
|
海通恆信:創新不息 驅動新質生產力發展行穩致遠
Apr 23, 2025 16:33 HKT/SGT
|
|
|
海通恒信:创新不息 驱动新质生产力发展行稳致远
Apr 23, 2025 16:19 HKT/SGT
|
|
|
アリックスパートナーズ、中国自動車市場の最新調査を発表
Apr 23, 2025 13:00: JST
|
|
|
裝機及發電雙增超47% 北京能源國際領跑清潔能源賽道
Apr 23, 2025 11:45 HKT/SGT
|
|
|
装机及发电双增超47% 北京能源国际领跑清洁能源赛道
Apr 23, 2025 11:28 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|